Semaglutide Linked to Rare Vision Loss: A Global Safety Alert
Background
Non-arteritic anterior ischemic optic neuropathy (NAION) is a sudden, painless vision loss caused by insufficient blood flow to the optic nerve, a serious ocular condition. While semaglutide, a widely used GLP-1 receptor agonist for type 2 diabetes and obesity, has shown various side effects, its association with NAION has presented conflicting evidence in recent observational studies. This review aims to synthesize available pharmacovigilance evidence and clinical case data to clarify the potential risk of NAION with semaglutide use.
Study Design
Results
The review identified a concerning and statistically significant association, indicating that semaglutide use may substantially increase the risk of NAION. Analysis of aggregated pharmacovigilance data from multiple sources consistently pointed towards a heightened risk for this serious ocular condition. The World Health Organization (WHO) issued a significant safety alert in 2025, specifically attributing a hazard ratio (HR) of 7.64 for NAION in patients using semaglutide, compared to non-users. This 7.64-fold increased risk represents a strong and urgent safety signal, suggesting that semaglutide could be a contributing factor to the development of NAION. The synthesis of clinical case data further corroborated this finding, detailing multiple instances of sudden, painless monocular vision loss occurring in patients shortly after initiating or escalating their semaglutide treatment, although specific patient numbers across all cases were not uniformly available in this review.
Why It Matters
This review provides a critical safety alert for clinicians prescribing semaglutide, emphasizing the need for increased vigilance regarding ocular symptoms. The findings suggest that patients on semaglutide should be informed about the potential, albeit rare, risk of NAION and advised to seek immediate medical attention for any sudden vision changes. Understanding this risk is crucial for patient counseling and could lead to updated prescribing information and monitoring guidelines. Future pharmacovigilance studies and potentially prospective observational studies are needed to further quantify this risk and elucidate underlying mechanisms.